2,5-dimethoxy-4-chloroamphetamine, a LSD-like designer drug: Clinical and analytical documentation of non-fatal exposure in five patients

Maurer, 2010, Chemistry, pharmacology, and metabolism of emerging drugs of abuse, Ther Drug Monit, 32, 544, 10.1097/FTD.0b013e3181eea318 Soares, 2004, Simultaneous determination of amphetamine derivatives in human urine after SPE extraction and HPLC-UV analysis, Biomed Chromatogr, 18, 125, 10.1002/bmc.315 Curtis, 2003, Postmortem identification and quantitation of 2,5-dimethoxy-4-n propylthiophenethylamine using GC-MSD and GC-NPD, J Anal Toxicol, 27, 493, 10.1093/jat/27.7.493 Hill, 2011, Clinical toxicology of newer recreational drugs, Clin Toxicol (Phila), 49, 705, 10.3109/15563650.2011.615318 Kerrigan, 2014, Designer psychostimulants in urine by liquid chromatography-tandem mass spectrometry, J Forensic Sci, 59, 175, 10.1111/1556-4029.12306 Shulgin, 1997 Ovaska, 2008, First case report of recreational use of 2,5-dimethoxy-4-chloroamphetamine confirmed by toxicological screening, Eur J Emerg Med, 15, 354, 10.1097/MEJ.0b013e3282fc765b Burish, 2015, Hallucinogens causing seizures? A case report of the synthetic amphetamine 2,5-dimethoxy-4-chloroamphetamine, Neurohospitalist, 5, 32, 10.1177/1941874414528939 Barnett, 2014, A fatal intoxication of 2,5-dimethoxy-4-chloroamphetamine: a case report, J Anal Toxicol, 38, 589, 10.1093/jat/bku087 Ferec, 2016, Severe serotoninergic syndrome after ingestion of α-methyl-tryptamine, Toxac, 28, 71 Gruson, 2005, Aide à la validation des méthodes en toxicologie et suivi thérapeutique pharmacologique, Ann Toxicol Anal, S1, 1 Matuszewski, 2003, Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS, Anal Chem, 75, 3019, 10.1021/ac020361s Balíková, 2005, Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetamine) overdose, Forensic Sci Int, 153, 85, 10.1016/j.forsciint.2005.04.022 Wood, 2007, Collapse, reported seizure – and an unexpected pill, Lancet, 369, 1490, 10.1016/S0140-6736(07)60674-6 Staack, 2007, Piperazine designer drugs of abuse, Lancet, 369, 1411, 10.1016/S0140-6736(07)60646-1